Differentiation of inodilatory responses by non-invasive measures of cardiovascular performance in healthy man

International Journal of Clinical Pharmacology and Therapeutics

Volumn 34, Issue 12, 1996, Pages 525-532

  De Mey, C ^a   Erb, K ^b   Schroeter, V ^c   Belz, G G ^c  

^a Iphar Institute for Clinical Pharmacology   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Ctr of Cardiovascular Pharmacology   (Germany)

Author keywords

Adrenaline; Bimakalim; Celiprolol; Impedance cardiography; Inodilation; Isoprenaline; Phosphodiesterase inhibition; Systolic time intervals

Indexed keywords

ADRENALIN; BIMAKALIM; BISOPROLOL; BISOPROLOL FUMARATE; CELIPROLOL; ISOMAZOLE; ISOPRENALINE; MERIBENDAN; METOPROLOL TARTRATE; PHOSPHODIESTERASE INHIBITOR; TALINOLOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR PERFORMANCE; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEART VENTRICLE EJECTION TIME; HUMAN; HUMAN EXPERIMENT; IMPEDANCE CARDIOGRAPHY; INOTROPISM; INTRAVENOUS DRUG ADMINISTRATION; MALE; META ANALYSIS; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; SYSTOLIC TIME INTERVAL; VASCULAR RESISTANCE; VASODILATATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADULT; BENZOPYRANS; CARDIOTONIC AGENTS; CELIPROLOL; CROSS-OVER STUDIES; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HEMODYNAMIC PROCESSES; HUMANS; ISOPROTERENOL; MALE; MONITORING, PHYSIOLOGIC;

EID: 0030453936     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Alken RG, Belz GG 1984 A comparative dose-effect study with cardiac glycosides assessing cardiac and extracardiac responses in healthy subjects. J Cardiovasc Pharmacol 6:634-640
2. Belz GG 1995 Dose-effect and kinetic-dynamic relationships of the β-adrenoceptor blocking properties of various doses of talinolol in healthy man. J Cardiovasc Pharmacol 26:879-888
3. Belz GG, Aust PE, Schneider B 1981 Time course of the effects of single intravenous doses of digitoxin and digoxin in normal volunteers. J Cardiovasc Pharmacol 3:1116-1125
4. Belz GG, Schroeter V, de Mey C, Butzer R, Buhring KU, Ungethum W, Leopold G 1992 Effect-concentration-relationships for the PDE-111-phosphodiesterase inhibitors isomazole and meribendan in healthy man. Clin Pharmacol Ther 51:152
5. Boudoulas H 1991 Systolic time intervals. In: Robertson JIS, Birkenhager WH (eds) Cardiac Output Measurement Saunders, London, pp 93-104
6. Breithaupt-Grögler K, de Mey C, Leschinger M, Trenk D, Jahnchen E, Schreck W, Dieterich HA, Belz GG 1993 Cardiovascular effects of enoximone, captopril and their combination in healthy man. Klin Pharmakol Akt 2:36(P322)
7. de Mey C 1995 Method specificity of the auscultatory estimates of the inodilatory reduction of diastolic blood pressure based on Korotkoff-IV and -V criteria. Br J Clin Pharmacol 39:485-490
8. de Mey C, Enterling D 1987 Non-invasive estimates of cardiac performance during and immediately after single and repeated passive upright tilt in normal man: volume dependency of systolic time intervals and maximum velocity of transthoracic impedance changes. Am J Noninvasive Cardiol 1:188-196
9. de Mey C, Enterling D 1993 Disagreement between standard transthoracic impedance cardiography and the automated transthoracic electrical bioimpedance method in estimating cardiovascular performance in healthy man. Br J Clin Pharmacol 35:349-355
10. de Mey C, Erb KA Usefulness, usability and quality criteria of non-invasive methods in cardiovascular clinical pharmacology. J Clin Pharmacol in press
11. de Mey C, Hansen-Schmidt S, Enterling D 1988 Postprandial haemodynamic changes: a source of bias in cardiovascular research affected by its own methodological bias. Cardiovasc Res 22:703-707
12. de Mey C, Enterling D and Hanft G 1991a Noninvasive assessment of the inodilatory effects of amrinone in healthy man. Eur J Clin Pharmacol 40:373-378
13. de Mey C, Enterling D and Hanft G 1991b Noninvasive monitoring of systematic and exceptional effects of an investigational PDE kl phosphodiesterase inhibitor in normal man. Am J Noninvasive Cardiol 5:115-120
14. de Mey C, Belz GG, Nixdorf U, Butzer R, Schroeter V, Meyer J, Erbel R 1992a Relative sensitivity of four methods in assessing systolic cardiovascular effects of isoprenaline in healthy volunteers. Clin Pharmacol Ther 52:609-619
15. de Mey C, Matthews J, Butzer R, Schroeter V and GG Belz 1992b Agreement and reproducibility of the estimates of cardiovascular function by impedance cardiography and M-mode echocardiography in healthy subjects. Br J Clin Pharmacol 34:88-92
16. de Mey C, Elich D, Schroeter V, Buker R, Belz GG 1992c Captopril does not interact with the pharmacodynamics and pharmacokinetics of digitoxin in healthy man. Eur J Clin Pharmacol 43:445-447
17. 1-adrenoceptor antagonist bisoprolol on the cardiovascular actions and βadrenoceptor subtype specific occupancies subsequent to the administration of celiprolol in healthy man. Eur J Clin Pharmacol 44:341-348
18. de Mey C, Erb K, Ungethüm W, Leopold G, Belz GG 1993b Cardiovascular effects of bimakalim, bisoprolol and the interaction in healthy man. Clin Pharmacol Ther 53:204
19. de Mey C, Schroeter V, Roll S, Jahn P, Palm D, Terhaag B, Belz GG 1994a Clinical pharmacology of talinolol, a β-adrenoceptor antagonist with high relative β1-adrenoceptor selectivity in man. Naunyn-Schmied Archiv Pharmacol 349(suppl): R 143
20. de Mey C, Hoffman JA, Herrmann M, Schroeter V, Belz GG 1994b Contrasting cardiovascular effects of celiprolol and metoprolol at doses with similar β1- and β2-adrenoceptor occupancies in man. Naunyn-Schmied Archiv Pharmacol 349 (Suppl):R142
21. de Mey C, Breithaupt K, Schloos J, Neugebauer G, Palm D and Belz GG 1994c Dose-effect and pharmacokinetic-pharmacodynamic relationships of the β1-adrenoceptor blocking properties of various doses of carvedilol in healthy man. Clin Pharmacol Ther 55:329-337
22. de Mey C, Schroeter V, Butzer R, Jahn P, Wetterich U, Terhaag B, Mutschler E, Spahn-Langguth H, Palm D, Belz GG 1995 Dose-effect and kinetic-dynamic relationships of the β-adrenoceptor blocking properties of various doses of talinolol in healthy man. J Cardiovasc Pharmacol 26:879-888
23. Dietz U, Belz GG 1991 Low frequency arterial wall movements for indirect blood pressure measurement in man. Arzneimittelforschung 41:557-562
24. Ensinger H, Lindner KH, Dirks B, Kilian J, Grunert A, Ahnefeld FW 1992 Adrenaline: relationship between infusion rate, plasma concentration, metabolic and haemodynamic effects in volunteers. Eur J Anaesth 9:435-446
25. Gibson DG 1978 Use of systolic time intervals in clinical pharmacology. Br J Clin Pharmacol 6:97-102
26. Good Clinical Practice for Trials on Medicinal Products in the European Community 1990 Note for Guidance II/3976/88-EN 04-05.
27. Haustein K-O, Fiering H, Oltmanns G et al1979 On the clinical pharmacology of talinolol, a new beta1-adrenoceptor blocking agent. Int J Clin Pharmacol Therap 17:465-470
28. Hayes JS, Bowling N, Pollok GD, Robertsan DW 1986 Roles of Ca++ and cyclic AMP in mediafing the cardiotonic actions of isomazole (LY175326). J Pharmacol Exp Ther 237:18-24
29. Hayes JS, Pollack GD, Wilson H, Bowling N, Robertson DW 1985 Pharmacology of LY175326: a potent cardiotonic agent with vasodilator activities. J Pharmacol Exp Ther 223:318-326
30. Heather LW A comparison of cardiac output values by the impedance cardiography and dye diluation techniques in cardiac patients. In: Kubicek WG, Witsoe DA, Patterson RP (eds) 1969 Development and Evaluation of an Impedance Cardiographic System to Measure Cardiac Output and Other Cardiac Parameters. NASA-CR-101965, Houston, NASA
31. Joubert P, Belz GG 1987 Are preejection period changes specific for inotropic effects? Eur J Clin Pharmacol 33:335-336
32. Kubicek WG, Karnegis JN, Patterson RP, Witsoe DA, Mattson RH 1966 Development and evaluation of an impedance cardiac output system. Aerosp Med 37:1208-1212
33. Li Q, Belz GG 1993 Systolic time intervals in clinical pharmacology. Eur J Clin Pharmacol 44:415-421
34. Mäntysaari M, Länsimes E 1992 Heart rate correction based on "universal" regression equation - erroneous conclusions drawn when studying cardiac mechanical function during stress. Eur Heart J 13:1088-1091
35. Merck E 1987 Isomazole hydrochloride: LY-175326: EMD-41064. Drugs of the Future 12:400
36. Milne RJ, Buckley M 1991 Celiprolol - an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in cardiovascular disease. Drugs 41:941-969
37. Mohapatra SN 1981 Non-invasive cardiovascular monitoring by electrical impedance technique. Pitman Medical, London
38. Nakamura Y, Wiegner AW, Gasch WH, Bing OHL 1983 Systolic time intervals: assessment by isolated cardiac muscle studies. J Am Coll Cardiol 2:973-978
39. Opie LH 1986 Inodilators. Lancet 1:1336
40. Richer C, Pratz J, Mulder P, Mondot S, Giudicelli JF, Cavero I 1990 Cardiovascular and biological effects of K+ channel openers, a class of drugs with vasorelaxam and cardioprotective properties. Life Sci 47: 1693-1705
41. Rousson D, Galleyrand J, Silie M, Boissel JP 1987 Unconnected pre-ejection period: a simple non-invasive measurement for pharmacodynamic screening of inotropic activity. Eur J Clin Pharmacol 31:559-562
42. Spadick DH, Ball HG, Pigott VM 1978 Effects of recording speeds on precision of time-based polycardiographic measurements. Br Heart J 40:1344-1348
43. Spodick DH, Doi YL, Bishop RL, Hashimoto T 1996 Systolic time intervals reconsidered. Reevaluation of the preejection period: absence of relation to heart rate. Am J Cardiol 53:1667-1670
44. Stern HC, Matthews JH, Belz GG 1984 Influence of dihydralazine induced afterload reduction on systolic time intervals and echocardiography in healthy subjects. Br Heart J 52:435-439
45. Taylor SH 1988 Celiprolol and the heart. Am J Cardiol 61:34C-40C
46. van Woerkens W, Baas NRA, van der Giessen WJ, Verdouw PD 1992 Cardiovascular effects of the novel potassium channel opener bimakalim in conscious pigs after myocardial infarction: a comparative study with nicorandil. Cardiovasc Drugs Ther 6:409-417
47. Warrington SJ, Weerasuriya K, Burgess CD 1988 Correction of systolic time intervals for heart rate: a comparison of individual with population derived regression equations. Br J Clin Pharmacol 26::155-165
48. Weissler AM, Harris WS, Schoenfeld CD 1969 Bedside techniques for the evaluation of ventricularfunction in man. Am J Cardiol 23:577-583
49. Weissler AM, Garrard CL 1971 Systolic time intervals in cardiac disease. Mod Concepts Cardiovasc Dis 40: 1-4
50. Weston AH, Edwards G 1992 Recent progress in potassium channel opener pharmacology. Biochem Pharmacol 43:47-54
51. Wezler K und Boger A 1939 Die Dynamik des arteriellen Systems. Ergebn Physiol 41:291-606
52. Wolf GK, Belz GG, Stauch M 1978 Systolic time intervals -correction for heart rate. Basic Res Cardiol 73:85-96